Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast

Prostaglandins and Other Lipid Mediators

Volumn 83, Issue 4, 2007, Pages 257-267

  Şener, Göksel ^a   Sakarcan, Abdullah ^b   Şehirli, Özer ^a   Ekşioǧlu Demiralp, Emel ^a   Şener, Emre ^a   Ercan, Feriha ^a   Gedik, Nursal ^c   Yeǧen, Berrak Ç ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KASIMPASA MILITARY HOSPITAL   (Turkey)

Author keywords

Chronic renal failure; Inflammation; Leukotriene; Oxidative injury

Indexed keywords

AUTACOID; COLLAGEN; CREATININE; GLUTATHIONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LEUKOTRIENE B4; MALONALDEHYDE; MONTELUKAST; MYELOPEROXIDASE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BRAIN TISSUE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FIBROSIS; FLOW CYTOMETRY; HEART; HISTOPATHOLOGY; KIDNEY MASS; KIDNEY PARENCHYMA; LEUKOCYTE; LUNG PARENCHYMA; MALE; MICROSCOPY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; RAT; TISSUE INJURY; TREATMENT DURATION; WISTAR RAT;

ACETATES; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOOD UREA NITROGEN; COLLAGEN; CREATININE; GLUTATHIONE; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY; KIDNEY FAILURE, CHRONIC; L-LACTATE DEHYDROGENASE; LEUKOCYTES; LEUKOTRIENE ANTAGONISTS; LUNG; MALE; MALONDIALDEHYDE; MEMBRANE PROTEINS; MULTIPLE ORGAN FAILURE; QUINOLINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, LEUKOTRIENE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248171190     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.01.013     Document Type: Article

References (52)

1. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 24 (2004) 469-473
2. Owen W.F., and Lowrie E.G. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54 (1998) 627-636
3. Caglar K., Hakim R.M., and Ikizler T.A. Approaches to the reversal of malnutrition, inflammation, and atherosclerosis in end-stage renal disease. Nutr Rev 60 (2002) 378-387
4. Zimmermann J., Herrlinger S., Pruy A., Metzger T., and Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658
5. Kishore B.K., Gejyo F., and Arakawa M. Malondialdehyde: a putative uremic toxin IRCS. Med Sci 11 (1983) 750-751
6. Trznadel K., Pawlicki L., Kedziora J., Luciak M., Blaszczyk J., and Buczynski A. Superoxide anion generation, erythrocytes superoxide dismutase activity, and lipid peroxidation during hemoperfusion and hemodialysis in chronic uremic patients. Free Radic Biol Med 6 (1989) 393-397
7. Paul J.L., Man N.K., Moatti N., and Raichvarg D. Membrane phospholipid peroxidation in renal insufficiency and chronic hemodialysis. Nephrologie 12 (1991) 4-7
8. Vaziri N.D., Oveisi F., and Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 53 (1998) 1748-1754
9. Maruyama Y., Lindholm B., and Stenvinkel P. Inflammation and oxidative stress in ESRD-the role of myeloperoxidase. J Nephrol 17 (2004) 72-76
10. Cassatella M.A., Gasperini S., and Russo M.P. Cytokine expression and release by neutrophils. Ann N Y Acad Sci 832 (1997) 233-242
11. Ishikawa F., and Miyazaki S. New biodefense strategies by neutrophils. Arch Immunol Ther Exp 53 (2005) 226-233
12. Kelly K.J., Williams W.W., Colvin R.B., et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 97 (1996) 1056-1063
13. Damtew B., Marino J.A., Fratianne R.B., and Spagnuolo P.J. Neutrophil lipoxygenase metabolism and adhesive function following acute thermal injury. J Lab Clin Med 121 (1993) 328-336
14. Wallace J.L., Beck P.L., and Morris G.P. Is there a role for leukotrienes as mediators of ethanol-induced gastric mucosal damage?. Am J Physiol 254 (1988) G117-G123
15. Carsin H., Bargues L., Stephanazzi J., Paris A., Aubert P., and Le Bever H. Inflammatory reaction and infection in severe burns. Pathol Biol 50 (2002) 93-101
16. Wallace J.L., McKnight G.W., Keenan C.M., Byles N.I., and MacNaughton W.K. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology 98 (1990) 1178-1186
17. Konturek S.J., Brozozowski T., Drozdowicz D., and Beck G. Role of leukotrienes in acute gastric lesions induced by ethanol, taurocholate, aspirin, platelet-activating factor and stress in rats. Dig Dis Sci 33 (1988) 806-813
18. Şener G., Kabasakal L., Çetinel S., Contuk G., Gedik N., and Yegen B. Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs. Burns 31 (2005) 587-596
19. Şener G., Şehirli O., Çetinel S., et al. Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast. Prostoglandins Leukot Essent Fatty Acids 73 (2005) 453-462
20. Sener G., Sehirli O., Velioglu-Ogunc A., et al. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res 54 (2006) 573-579
21. Vaziri N.D., Dicus M., Ho N.D., Boroujerdi-Rad L., and Sindhu R.K. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63 (2003) 179-185
22. Slot C. Plasma creatinine determination. A new and specific Jaffe reaction method. Scand J Clin Lab Invest 17 (1965) 381-387
23. Talke H., and Schubert G.E. Enzymatic urea determination in the blood and serum in the Warburg optical test. Klinische Wochenschrift 43 (1965) 174-175
24. Martinek R.G. A rapid ultraviolent spectrophotomeetric lactic dehydrogenase assay. Clin Chem Acta 40 (1972) 91-99
25. Beuge J.A., and Aust S.D. Microsomal lipid peroxidation. Meth Enzymol 53 (1978) 302-311
26. Beutler E. Glutathione in red blood cell metabolism. A manual of biochemical methods (1975), Grune & Stratton, New York p. 112-4
27. Bradley P.P., Priebat D.A., Christersen R.D., and Rothstein G. Measurement of cutaneous inflammation. Estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78 (1982) 206-209
28. Hillegass L.M., Griswold D.E., Brickson B., and Albrightson-Winslow C. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Meth 24 (1990) 285-295
29. Lopez De Leon A., and Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed parraffin-embedded sections. J Histochem Cytochem 33 (1985) 737-743
30. Katoh T., Lianos E.A., Fukunaga M., Takahashi K., and Badr K.F. Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis. J Clin Invest 91 (1993) 1507-1515
31. Takamatsu Y., Shimada K., Chijiiwa K., Kuroki S., Yamaguchi K., and Tanaka M. Role of leukotrienes on hepatic ischemia/reperfusion injury in rats. J Surg Res 119 (2004) 14-20
32. Baba T., Black K.L., Ikezaki K., Chen K.N., and Becker D.P. Intracarotid infusion of leukotriene C4 selectively increases blood-brain barrier permeability after focal ischemia in rats. J Cereb Blood Flow Metab 11 (1991) 638-643
33. Yu G.L., Wei E.Q., Zhang S.H., et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal ischemia in mice. Pharmacology 73 (2005) 31-40
34. Zhang S.H., Wei E.Q., Zhu C.Y., Chen Z., and Zhang S.F. Protective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia induced by endothelin-1 in rats. Acta Pharm Sin 39 (2004) 1-4
35. Maccarrone M., Manca-di-Villahermosa S., Meloni C., et al. Arachidonate cascade, apoptosis, and vitamin E in peripheral blood mononuclear cells from hemodialysis patients. Am J Kidney Dis 40 (2002) 600-610
36. Massy Z.A., and Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol 15 (2002) 336-341
37. Stenvinkel P., Ketteler M., Johnson R.J., et al. IL-10, IL-6 and TNF-a: central factors in the altered cytokine network of uremia-the good, the bad and the ugly. Kidney Int 67 (2005) 1216-1233
38. Djaldetti M., Salman H., Bergman M., Djaldetti R., and Bessler H. Phagocytosis-the mighty weapon of the silent warriors. Microsc Res Tech 57 (2002) 421-431
39. Handelman G.J., Walter M.F., Adhikarla R., et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59 (2001) 1960-1996
40. Nguyen-Khoa T., Massy Z.A., De Bandt J.P., et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16 (2001) 335-340
41. Diepeveen S.H.A., Verhoeven G.H., van der Palen J., et al. Oxidative stress in patients with end-stage renaldisease prior to the start of renal replacement therapy. Nephron Clin Pract 98 (2004) c3-c7
42. Annuk M., Fellstrom B., Akerblom O., Zilmer K., Vihalemm T., and Zilmer M. Oxidative stress markers in pre-uremic patients. Clin Nephrol 56 (2001) 308-314
43. 2-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol 33 (2001) 775-783
44. Oberg B.P., Mc Menamin E., Lucas F.L., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic renal disease. Kidney Int 65 (2004) 1009-1016
45. Ece A., Atamer Y., Gurkan F., et al. Paraoxonae, anti-oxidant response and oxidative stress in children with chronic renal failure. Pediatr Nephrol 21 (2006) 239-245
46. Patel N.S., Cuzzocrea S., Chatterjee P.K., et al. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 66 (2004) 220-227
47. Sullivan G.W., Sarembock I.J., and Linden J. The role of inflammation in vascular diseases. J Leukocyte Biol 67 (2000) 591-602
48. Reiter R.J., Tan D.X., Osuna C., and Gitto E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 7 (2000) 444-458
49. Weiss S.J., and Ward P.A. Immune complex induced generation of oxygen metabolites by human neutrophils. J Immunol 129 (1982) 309-313
50. Malle E., Buch T., and Grone H.J. Myeloperoxidase in kidney disease. Kidney Int 64 (2003) 1956-1967
51. Matsui N., Fukuishi N., Fukuyama Y., Yasui Y., and Akagi M. Protective effect of the 5-lipoxygenase inhibitor ardisiaquinone on hepatic ischemia-reperfusion injury in rats. Planta Med 71 (2005) 717-720
52. Noiri E., Yokomizo T., Nakao A., et al. An in vivo approach showing the chemotactic activity of leukotriene B4 in acute renal ischemic-reperfusion injury. Proc Natl Acad Sci 97 (2000) 823-828